EBSCO Logo
Connecting you to content on EBSCOhost
Results
Title

Potential drug–drug interactions analysis in Polish pediatric pneumonology units, including cystic fibrosis patients.

Authors

Adamiszak, Arkadiusz; Drobińska, Julia; Wojsyk‐Banaszak, Irena; Grześkowiak, Edmund; Bienert, Agnieszka

Abstract

The lack of data on drug–drug interactions in pediatrics represents a relevant problem in making appropriate therapeutic decisions. Our study aimed to investigate the incidence and risk factors for potential drug–drug interactions (pDDIs) in pediatric pneumonology units, including cystic fibrosis patients. We performed a 6‐month prospective observational study during which clinical pharmacists, using the Lexicomp Drug Interactions checker, screened medical records to identify pDDIs. Spearman's rank coefficient, logistic regression, and the Mann–Whitney U test were used to identify correlations, analyze risk factors for pDDIs, and compare cystic fibrosis patients with the rest, respectively. Recommendations were provided for the D and X pDDIs categories. Within the 218 patients, 428 pDDIs were identified, out of which 237 were classified as clinically significant. Almost 60% of patients were exposed to at least one relevant interaction. The number of pDDIs correlated with the number of; drugs (rs = 0.53, P <.001), hospitalization length (rs = 0.20, P <.01), and off‐label medicines (rs = 0.25, P <.001). According to the multivariate analysis, at least 6 administered medications (OR = 4.15; 95% CI = 2.21‐7.78), 4 days of hospitalization (OR = 6.41; 95% CI = 2.29‐17.97), and off‐label therapy (OR = 3.37; 95% CI = 1.69‐6.70) were the risk factor for pDDIs. Despite significant differences in the number of medications taken, comorbidities, and off‐label drugs, cystic fibrosis patients were not more exposed to pDDI. Given the lack of data on pDDIs in the pediatric population, the need for close cooperation between clinicians and clinical pharmacists to improve the safety and efficacy of pharmacotherapy is highlighted.

Subjects

POLAND; RISK assessment; OFF-label use (Drugs); DATA analysis; LOGISTIC regression analysis; QUESTIONNAIRES; CHILDREN'S hospitals; MANN Whitney U Test; MULTIVARIATE analysis; ODDS ratio; DRUG interactions; STATISTICS; CONFIDENCE intervals; LENGTH of stay in hospitals; CYSTIC fibrosis; PULMONOLOGY; DISEASE incidence; CHILDREN

Publication

Journal of Clinical Pharmacology, 2024, Vol 64, Issue 10, p1326

ISSN

0091-2700

Publication type

Academic Journal

DOI

10.1002/jcph.2478

EBSCO Connect | Privacy policy | Terms of use | Copyright | Manage my cookies
Journals | Subjects | Sitemap
© 2025 EBSCO Industries, Inc. All rights reserved